资金面上看，两市主力资金全天净流出143.37亿元，今日有10个行业主力资金净流入，轻工制造行业主 力资金净流入规模居首，该行业今日上涨1.52%，全天净流入资金9.30亿元，其次是房地产行业，日涨 幅为1.68%，净流入资金为9.17亿元。 主力资金净流出的行业有21个，电子行业主力资金净流出规模居首，全天净流出资金44.75亿元，其次 是医药生物行业，净流出资金为34.30亿元，净流出资金较多的还有通信、计算机、机械设备等行业。 医药生物行业今日下跌0.97%，全天主力资金净流出34.30亿元，该行业所属的个股共474只，今日上涨 的有176只，涨停的有6只；下跌的有277只。以资金流向数据进行统计，该行业资金净流入的个股有171 只，其中，净流入资金超5000万元的有5只，净流入资金居首的是联环药业，今日净流入资金1.15亿 元，紧随其后的是宝莱特、联影医疗，净流入资金分别为8373.92万元、7667.30万元。医药生物行业资 金净流出个股中，资金净流出超亿元的有8只，净流出资金居前的有广生堂、长春高新、京新药业，净 流出资金分别为2.28亿元、1.51亿元、1.37亿元。（数据宝） 医药生物行业资金 ...

Core Viewpoint - The article highlights the launch of a large-scale public welfare initiative by United Imaging Healthcare in Luoping County, Yunnan Province, focusing on mobile medical services and early disease screening, particularly for lung-related conditions [1][5][6]. Group 1: Initiative Overview - The "Change in the County" mobile medical public welfare initiative has reached its fourth stop in Luoping County, Yunnan, supported by local health authorities and medical associations [1]. - The initiative includes grassroots training and public screening conducted at local hospitals and community health centers [1][5]. Group 2: Health Concerns and Screening Focus - Luoping County's primary industries, such as rapeseed and coal mining, expose workers to respiratory diseases, necessitating targeted health screenings [5]. - The public screening primarily focuses on lung function tests, utilizing United Imaging's mobile CT technology to detect conditions like lung nodules and emphysema [5][6]. Group 3: Early Detection and Community Impact - The initiative has successfully identified several early-stage lung cancer patients, emphasizing the importance of early diagnosis in improving treatment outcomes and reducing healthcare costs [6]. - United Imaging's local director expressed commitment to enhancing healthcare access through mobile services and comprehensive cancer care management [6]. Group 4: Broader Goals and Achievements - Since its launch in August 2024, the initiative has expanded to various rural areas, aiming to deliver high-quality medical resources to underserved regions [6]. - The mobile medical bus has facilitated early diagnosis and screening for thousands of residents, focusing on diseases like lung cancer [6].

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **domestic medical device industry**, highlighting advancements in various companies and their innovative products. Key Companies and Their Innovations 1. **Peijia Medical** - The shockwave balloon technology shows a **30%-50% efficacy** in early clinical trials for treating aortic valve calcification [1] - The transcatheter aortic valve replacement product **Mona Q** has enrolled **9 patients** in the global Fame clinical trial, with no deaths or strokes reported during long-term follow-up. It has received **IDE clinical approval** in the U.S. and is expected to advance to U.S. clinical trials within the year [2][4] 2. **Jianxi Technology** - The tricuspid valve replacement product has completed clinical registration trials in Europe with a **97% success rate** and is expected to receive CE certification by **2025** [1][3] 3. **Xenon Medical** - The self-expanding intracranial drug-eluting stent has a **restenosis rate of only 1.7%-1.87%** and a **100% surgical success rate**. Approval is anticipated this year, with a market exclusivity period of **1.5 to 2 years** [1][6][7] 4. **HeartTech Medical** - Leading market share in domestic occluder products with a series of **four generations of biodegradable occluders**. The aortic valve product has been approved for commercialization since Q1 [1][8] 5. **Qiming Medical** - Four TAVI products have been approved and marketed in over **ten countries**. New TAVI products are under development, with expectations for a tricuspid valve replacement product to be approved in Europe by **2027** [1][9] Market Trends and Future Outlook - The medical device sector is expected to see a **catalyst for growth** in the second half of the year due to potential equipment upgrades, particularly in **3.0T MRI and 64-slice CT** products [2][17] - Companies like **Huitai Medical** are projected to have strong performance due to new product launches and market expansion [11][23] Competitive Strategies - Domestic medical device companies are enhancing their international competitiveness through: - **Patent breakthroughs** and early clinical trials [4] - Focusing on less crowded market segments for differentiation [4] - Collaborations with international firms to leverage global networks for faster commercialization [5] Financial Performance Expectations - Companies such as **Huitai Medical** and **Mingrui Medical** are expected to show strong growth in the second half of the year, despite some companies facing short-term pressures due to high bases from previous years [10][11][15] - The **IVD sector** is experiencing pressure from policy changes, but improvements are anticipated in the latter half of the year as companies adjust pricing strategies [28] Regulatory and Policy Impact - The medical industry is facing challenges from **DRG cost control policies** and increased compliance requirements, impacting overall performance and cash flow [33] Conclusion - The domestic medical device industry is poised for growth with innovative products and strategic collaborations, despite facing regulatory challenges and market competition. Companies are actively seeking to enhance their international presence and capitalize on emerging market opportunities.

Core Viewpoint - The performance of the CSI All Index for Medical Care Equipment and Services has shown mixed results, with a slight increase on the day but a decline over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI All Index for Medical Care Equipment and Services rose by 0.21% to 13,548.3 points, with a trading volume of 19.92 billion [1]. - Over the past month, the index has decreased by 1.41%, by 2.78% over the past three months, and by 1.24% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the medical care sector, reflecting the overall performance of these securities [1]. - The index was established on December 31, 2004, with a base point of 1,000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: Mindray Medical (9.65%), United Imaging (8.18%), Aier Eye Hospital (7.43%), Aimeike (3.42%), Huatai Medical (3.23%), Yuyue Medical (2.81%), New Industry (2.79%), Lepu Medical (2.69%), Meinian Onehealth (2.06%), and Shandong Pharmaceutical Glass (1.9%) [1]. Group 4: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.10%) and the Shanghai Stock Exchange (39.90%) [1]. - The entire sample of the index is focused on the pharmaceutical and healthcare sector, with a 100% allocation [1]. Group 5: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the index include various Southern and Tianhong funds, as well as ETFs from multiple asset management companies [2].

Core Viewpoint - The company reported a decline in revenue and profit for 2024, but showed signs of recovery in Q1 2025, with a focus on both domestic and international market expansion [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan, a decrease of 9.73%, and a net profit of 1.262 billion yuan, down 36.1% [1]. - Q4 2024 revenue was 3.35 billion yuan, down 15.91%, with a net profit of 591 million yuan, down 35.1% [1]. - In Q1 2025, revenue increased to 2.478 billion yuan, up 5.42%, with a net profit of 370 million yuan, up 1.87% [1]. Business Segments - Domestic sales of medical imaging and radiation therapy equipment generated 8.445 billion yuan, a decline of 14.93%, while the service segment grew by 26.81% to 1.356 billion yuan [2]. - International revenue reached 2.266 billion yuan, an increase of 35.08%, accounting for 22% of total revenue, driven by market penetration in high-end segments [2]. R&D and Innovation - The company invested 2.261 billion yuan in R&D in 2024, representing 21.95% of revenue, and 568 million yuan in Q1 2025, accounting for 22.92% of revenue [3]. - The company has achieved significant advancements in technology across various product lines, establishing a competitive edge in the market [3]. Market Strategy - The company is focusing on a dual strategy of high-end product development and comprehensive market penetration domestically, while enhancing localized operations internationally [3]. - The global service network now covers over 85 countries and regions, supporting the operational needs of more than 34,500 devices [3].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 50 Index (Sci-Tech 50) opened higher and fluctuated, rising by 0.24% to 984.95 points with a trading volume of 19.704 billion yuan [1] - Over the past month, the Sci-Tech 50 Index has increased by 0.57%, but it has decreased by 3.92% over the past three months and by 0.64% year-to-date [2] - The Sci-Tech 50 Index consists of 50 securities with high market capitalization and liquidity from the Sci-Tech Innovation Board, reflecting the overall performance of representative Sci-Tech enterprises [2] Group 2 - The top ten weighted stocks in the Sci-Tech 50 Index are: SMIC (10.35%), Haiguang Information (8.5%), Cambricon (7.68%), Lattice Semiconductor (6.2%), Zhongwei Company (5.28%), Kingsoft Office (4.24%), United Imaging (4.21%), Transsion Holdings (2.35%), Chipone Technology (2.27%), and Ninebot (2.27%) [2] - The index is fully composed of stocks listed on the Shanghai Stock Exchange, with the information technology sector accounting for 68.86%, healthcare for 11.91%, industrials for 11.41%, consumer discretionary for 4.45%, materials for 2.72%, and consumer staples for 0.66% [2] Group 3 - The sample of the Sci-Tech 50 Index is adjusted quarterly, with adjustments occurring on the next trading day after the second Friday of March, June, September, and December [3] - The adjustment process allows for a maximum of 10% change in the number of samples, with a buffer rule prioritizing the top 40 candidates for inclusion and the top 60 existing samples for retention [3] - In cases of sample delisting, mergers, or other changes, the index will follow specific guidelines for replacement and adjustment [3]

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi showed a turnover rate of 5.93% with a transaction volume of 13.27 million yuan [2] - Over the past month, the average daily transaction volume reached 38.52 million yuan, ranking first among comparable funds [2] - In the past week, the Kexin Pharmaceutical ETF saw a significant scale increase of 16.98 million yuan, also ranking first among comparable funds [2] - The ETF's share increased by 15 million shares in the past week, marking a notable growth and leading among comparable funds [2] - In the last three days, the ETF experienced continuous net inflows, with a maximum single-day net inflow of 10.41 million yuan, totaling 18.13 million yuan [2] Group 2: Historical Performance - As of July 2, 2025, the Kexin Pharmaceutical ETF's net value increased by 30.63% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being five months and the maximum gain during this period being 23.50% [2] - The average return during the months of increase was 7.43%, with a historical one-year profit probability of 73.77% [2] Group 3: Index Composition - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index accounted for 50.3% of the total index [2] - The top stocks include: - United Imaging Healthcare (8.97% weight, +0.35% change) - BeiGene (7.05% weight, -0.05% change) - Huatai Medical (5.85% weight, -1.19% change) - Aier Eye Hospital (4.91% weight, -0.14% change) - Baillie Gifford (4.77% weight, +1.51% change) - Zai Lab (4.75% weight, +2.29% change) - BGI Genomics (4.17% weight, -0.73% change) - Junshi Biosciences (4.15% weight, +2.18% change) - Aibo Medical (3.33% weight, +0.25% change) - Teva Pharmaceutical (3.25% weight, -0.22% change) [4] Group 4: Policy Support - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on key issues faced by the industry [4] - The measures include 16 specific actions across five areas, aiming to provide comprehensive support for innovative drug research, access, hospital use, and multi-channel payment [4] Group 5: Industry Outlook - According to Industrial Securities, the innovative drug sector's prosperity is expected to be sustainable, with a focus on "innovation + internationalization" as the core direction of the pharmaceutical sector [5] - The sector is benefiting from policy support, enhanced global competitiveness, and the realization of commercial profitability [5] - Investors without stock accounts can access opportunities in the biopharmaceutical sector through the Kexin Pharmaceutical ETF Jiashi linked fund [5]

Company Overview - Shanghai United Imaging Healthcare Co., Ltd. specializes in providing high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital healthcare solutions globally [1] - The main products include MRI systems, CT systems, XR systems, molecular imaging systems, medical linear accelerators, animal MRI, animal PET/CT, United Imaging Cloud platform, cloud film, cloud PACS, and digital healthcare solutions [1] Financial Performance - For Q1 2025, the company reported revenue of 2.478 billion yuan, a year-on-year increase of 5.42% [2] - The net profit for the same period was 370 million yuan, reflecting a year-on-year growth of 1.87% [2] - The gross profit margin stood at 49.94% [2] Market Position - As of July 2, the company's stock closed at 126.15 yuan, down 1.48%, with a rolling PE ratio of 81.95 times [1] - The total market capitalization reached 103.968 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing the company at the 102nd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 21,435, up by 3,165 from the previous count [1] - The average market value of shares held per shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Intellectual Property - The company has applied for a total of 11,502 intellectual property rights, of which 5,882 have been granted [1] - During the reporting period, the company filed 1,079 new intellectual property applications and received 707 grants, including 766 invention patent applications and 465 granted invention patents [1]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.93% as of July 1, 2025, with notable gains from stocks such as Rongchang Biopharmaceutical (688331) up 7.21% and Shanghai Yizhong (688091) up 3.61% [1] - Starting July 1, 2025, a new policy mandates that all drug sales must include a verification code for medical insurance reimbursement, with full traceability of drug codes required by January 1, 2026, which is expected to enhance drug circulation regulation and impact the entire pharmaceutical industry chain [1] - The current bull market in innovative drugs is driven by the improvement of China's pharmaceutical innovation capabilities, with a trend towards international collaboration in new drug development expected to enhance profitability and market potential for Chinese pharmaceutical companies [2] Group 2 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - The Sci-Tech Biopharmaceutical ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in various biopharmaceutical sectors [2]

上海联影医疗科技股份有限公司关于公司董事离任 及选举第二届董事会职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2025 年 6 月 30 日召开股东会审议通过《关于取消监事会及修订 <公司章程> 的议 案》，根据《公司章程》，公司设职工代表董事 1 名，由公司职工通过职工代 表大会民主选举产生。公司于 2025 年 6 月 30 日召开职工代表大会并做出决 议，选举 TAO CAI 先生为公司第二届董事会职工董事。 证券代码：688271 证券简称：联影医疗 公告编号：2025-028 二、选举第二届董事会职工董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》（以下简称"《规范运作》"） 等相关法律法规，公司已于 2025 年 6 月 30 日召开股东会审议通过《关于取消监 事会及修订 <公司章程> 的议案》。 根据《公司章程》，公司设职工代 ...